Summary & Overview
CPT 81433: Molecular Diagnostic Testing in Pathology and Laboratory Medicine
CPT code 81433, previously used for molecular diagnostic testing in pathology and laboratory medicine, has been deleted effective January 1, 2025. This change affects laboratories nationwide that relied on this code for genetic analysis related to oncology and other clinical indications. The publication provides an overview of the code's clinical context, its typical use in laboratory settings, and the implications of its deletion for billing and reimbursement practices. Key payers covered include Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare, reflecting broad national coverage and relevance. Readers will gain insight into the code's historical application, associated diagnoses such as malignant neoplasms of the pancreas and breast, and related coding considerations. The summary also highlights important policy updates and benchmarks for pathology and laboratory services, equipping stakeholders with essential information for navigating upcoming changes in medical billing and coding.
CPT Code Overview
CPT 81433 was designated for pathology and laboratory services, specifically performed in a laboratory setting (POS 81). This code represented a molecular diagnostic procedure used to analyze genetic material, supporting clinical decision-making in oncology and other specialties. Effective January 1, 2025, CPT 81433 has been deleted from the CPT code set, impacting laboratories and providers who previously utilized this code for molecular testing.
Clinical & Coding Specifications
Clinical Context
A patient presents with a suspected or confirmed diagnosis of a malignant neoplasm involving the pancreas, peritoneum, or breast. The treating physician orders advanced molecular genetic testing to identify specific genetic mutations or alterations relevant to the cancer type. The laboratory receives the specimen and performs the analysis corresponding to CPT code 81433. Results are interpreted by a pathologist specializing in molecular genetic pathology. The findings assist in guiding treatment decisions, such as targeted therapies or eligibility for clinical trials. The service is typically performed in a laboratory setting (Place of Service 81), and the workflow involves specimen collection, laboratory processing, and professional interpretation.
Coding Specifications
-
Modifiers:
- Modifier
26: Used when reporting only the professional component (interpretation of results) of the laboratory service. - Modifier
TC: Used when reporting only the technical component (performance of the test) of the laboratory service. - Modifier
59: Used to indicate a distinct procedural service, typically when multiple procedures are performed and need to be reported separately.
- Modifier
-
Provider Taxonomies:
| Taxonomy Code | Specialty Name |
|---|---|
207ZP0102X | Pathology - Clinical Pathology/Laboratory Medicine |
207ZP0105X | Pathology - Molecular Genetic Pathology |
207L00000X | Anatomic Pathology |
These taxonomies represent providers specializing in laboratory medicine, molecular genetic pathology, and anatomic pathology, all of whom may be involved in ordering, performing, or interpreting the test associated with CPT code 81433.
Related Diagnoses
-
C25.0: Malignant neoplasm of head of pancreas- Relevant for patients with cancer localized to the head of the pancreas, guiding molecular testing for targeted therapy.
-
C25.1: Malignant neoplasm of body of pancreas- Indicates cancer in the body of the pancreas, supporting the need for molecular analysis.
-
C25.2: Malignant neoplasm of tail of pancreas- Applies to malignancy in the tail of the pancreas, where genetic testing may inform treatment.
-
C25.3: Malignant neoplasm of pancreatic duct- Used for cancers originating in the pancreatic duct, relevant for molecular profiling.
-
C25.4: Malignant neoplasm of endocrine pancreas- Pertains to endocrine pancreatic tumors, which may require specialized genetic testing.
-
C25.7: Malignant neoplasm of other parts of pancreas- Covers cancers in less common pancreatic sites, justifying molecular analysis.
-
C25.8: Malignant neoplasm of overlapping sites of pancreas- For tumors spanning multiple pancreatic regions, molecular testing helps in comprehensive assessment.
-
C48.1: Malignant neoplasm of specified parts of peritoneum- Indicates peritoneal cancer, where molecular testing can aid in diagnosis and management.
-
C50.011: Malignant neoplasm of nipple and areola, right female breast- Relevant for breast cancer in the right nipple and areola, supporting genetic analysis.
-
C50.012: Malignant neoplasm of nipple and areola, left female breast- Applies to left-sided breast cancer, where molecular testing may be indicated.
-
C50.021: Malignant neoplasm of nipple and areola, right male breast- Used for male breast cancer, guiding molecular profiling for treatment decisions.
Related CPT Codes
81479: Duplication/deletion analysis panel for hereditary breast cancer‑related disorders
81479 is related to 81433 as both involve advanced molecular genetic testing panels. 81479 is commonly used for hereditary breast cancer analysis, while 81433 covers broader molecular testing for malignancies such as pancreatic and breast cancers. These codes may be used together when comprehensive genetic profiling is required, or as alternatives depending on the specific clinical indication and cancer type.
National Reimbursement Benchmarks
Nationally, the mean rate for CPT code 81433 among commercial payers is highest with UnitedHealth Group at $782.88, followed by Cigna at $641.76, Blue Cross Blue Shield at $399.72, and the BUCA average at $494.32. The BUCA mean rate is substantially higher than typical Medicare rates, highlighting a significant commercial premium for this code.
Rate dispersion varies notably across payers. Cigna shows the tightest range between the 25th and 75th percentiles ($55.50), indicating more consistent reimbursement. UnitedHealth Group has the widest spread ($782.50), reflecting considerable variability in contracted rates. Blue Cross Blue Shield and BUCA display moderate dispersion. The table and chart below present the full breakdown of national benchmarks for each payer.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.